Gladius Capital Management LP Boosts Stock Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Gladius Capital Management LP lifted its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 48.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,131 shares of the company’s stock after purchasing an additional 1,026 shares during the quarter. Gladius Capital Management LP’s holdings in iTeos Therapeutics were worth $34,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. PNC Financial Services Group Inc. lifted its stake in iTeos Therapeutics by 131.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 2,287 shares of the company’s stock valued at $25,000 after acquiring an additional 1,299 shares during the period. Federated Hermes Inc. boosted its holdings in iTeos Therapeutics by 4,648.4% in the fourth quarter. Federated Hermes Inc. now owns 2,944 shares of the company’s stock valued at $32,000 after purchasing an additional 2,882 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of iTeos Therapeutics by 348.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,140 shares of the company’s stock valued at $45,000 after buying an additional 3,216 shares during the last quarter. Signaturefd LLC lifted its holdings in shares of iTeos Therapeutics by 268.5% in the 4th quarter. Signaturefd LLC now owns 4,481 shares of the company’s stock valued at $49,000 after buying an additional 3,265 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in shares of iTeos Therapeutics in the third quarter worth about $51,000. Institutional investors and hedge funds own 97.16% of the company’s stock.

Wall Street Analyst Weigh In

ITOS has been the subject of a number of analyst reports. Wedbush reissued an “outperform” rating and issued a $18.00 price target (down from $25.00) on shares of iTeos Therapeutics in a report on Wednesday, March 6th. HC Wainwright reissued a “buy” rating and set a $44.00 price target on shares of iTeos Therapeutics in a report on Thursday, March 7th.

iTeos Therapeutics Price Performance

NASDAQ ITOS traded down $0.01 during trading hours on Thursday, reaching $12.19. The company’s stock had a trading volume of 84,546 shares, compared to its average volume of 269,939. iTeos Therapeutics, Inc. has a 1-year low of $8.20 and a 1-year high of $18.24. The company’s 50-day moving average is $11.64 and its two-hundred day moving average is $10.76. The firm has a market capitalization of $438.47 million, a price-to-earnings ratio of -3.87 and a beta of 1.27.

iTeos Therapeutics (NASDAQ:ITOS) last announced its earnings results on Wednesday, March 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.18. Equities analysts forecast that iTeos Therapeutics, Inc. will post -4.76 EPS for the current fiscal year.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.